Krystal Biotech (NASDAQ: KRYS) has seen its stock soar over 230% since 2021, driven by the successful launch of Vyjuvek, the first FDA-approved gene therapy for Dystrophic Epidermolysis Bullosa (DEB). This mid-cap biotech has turned profitable, reporting earnings per share of $6.84 in 2025, and is capitalizing on a high-demand market with approximately 1,200 DEB patients in the U.S. alone. The company’s strong sales growth, up 34% year over year to $389.1 million, positions it well for future expansion.

Despite its promising trajectory, Krystal Biotech faces challenges, including potential competition in the DEB market and the need to successfully develop new therapies from its pipeline, which includes treatments for cystic fibrosis and other rare diseases. While the company has a solid foundation, its long-term success hinges on maintaining its market position and effectively launching additional products.

For market professionals, Krystal Biotech represents a compelling investment opportunity in the biotech sector, but caution is warranted given the uncertainties surrounding its growth strategy and competitive landscape.

Source: fool.com